Quantcast

Latest Immunosuppressants Stories

2014-02-26 04:21:30

Company Initiates Joint U.S. and Japanese Registration Trial HONG KONG, Feb. 26, 2014 /PRNewswire/ -- OrbusNeich today announced that patient enrollment has been initiated in Japan in the pivotal clinical trial of the COMBO Dual Therapy Stent(TM) (COMBO Stent) employing a single Japan-U.S. protocol conducted as a Global Clinical Trial "proof-of-concept" under the framework of the joint Japan-U.S. Harmonization-By-Doing [HBD] initiative. The first patient was enrolled at Shonan...

2014-02-20 12:25:06

CHERRY HILL, N.J., Feb. 20, 2014 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to offer the latest MS Research Update, available as both a printed and online publication. This vital resource provides a comprehensive overview of research findings on the ten FDA-approved disease-modifying therapies for relapsing forms of multiple sclerosis (MS), as well as the latest study results on many experimental treatments currently under investigation. Directions...

2014-02-19 12:28:56

NEW YORK, LONDON, BERLIN, PARIS, February 19, 2014 /PRNewswire/ -- Reportstack has announced a newly published market intelligence report on Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 [http://www.reportstack.com/product/150599/pharmapoint-ulcerative-colitis-global-drug-forecast-and-market-analysis-to-2022.html ] . The global ulcerative colitis (UC) market value will increase steadily over the coming years, growing from almost $4.2 billion in 2012...

2014-02-06 23:24:53

MarketResearchReports.Biz announces addition of new report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description” to its database. Visit: http://www.marketresearchreports.biz/analysis/186872 Albany, NY (PRWEB) February 06, 2014 Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description Research...

2014-02-06 16:27:04

Unsealed federal lawsuit alleges that pharmaceutical giant engaged in unlawful marketing schemes involving blockbuster drugs Thalomid and Revlimid in cancer treatment, costing taxpayers hundreds of millions of dollars; charges of kickbacks to physicians in pushing for unapproved treatments LOS ANGELES and WASHINGTON, Feb. 6, 2014 /PRNewswire/ -- Leading whistleblower law firm Grant & Eisenhofer P.A. represents a key whistleblower in a false claims lawsuit unsealed today against...

2014-02-05 20:23:53

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/9lglrg/biologics_and) has announced the addition of the "Biologics and Biosimilars World Markets" [http://www.researchandmarkets.com/research/9lglrg/biologics_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Biologics are complex molecules manufactured through cell culture recombinant DNA technology. Biologics...

2014-01-27 12:29:27

Potential U.S. Commercialization Targeted for 2014 CHICAGO, Jan. 27, 2014 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced the FDA acceptance of its New Drug Application (NDA) for its lead product candidate, MPI-2505, a subcutaneous injectable methotrexate (MTX) in a ready-to-use injection device, for which the proposed indications are rheumatoid...

2014-01-22 12:26:41

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class InnovationFrontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation SummaryGBI Research has released a new pharmaceutical report, "Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation". This highly competitive market...

2014-01-13 12:28:03

LONDON, Jan. 13, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Next Generation Stent Technologies (Technical Insights) Milestones in stent technologies achieved through proper funding sources This research service (RS) is a study on the funding prospects in the stent market. Stents are one of the most breakthrough medical devices in the cardiology market. The RS delivers content on the prevalent investor climate in this industry, and attempts to...

2014-01-08 12:30:01

HORSHOLM, Denmark, Jan. 8, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 13/167,420, a patent which covers the diurnal-independent administration of Envarsus(®). The subject patent covers a method of administering Envarsus(®), Veloxis' once-daily formulation of tacrolimus employing the company's proprietary MeltDose(®)...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.